Skip to main content
Aeglea Aeglea
  • Contact
  • Privacy Policy
  • Term of Use
  • Purchase Terms
  • COVID-19 Statement
  • Company
    • About
    • Leadership
    • Partnering
    • Contact
  • Focus
    • Enzyme Therapeutics
    • Rare Metabolic Disease
    • Publications
  • Programs
    • Pipeline
    • Pegzilarginase
    • AGLE-177
    • Research Programs
    • Clinical Trials
  • Careers
    • Job Openings
    • Life at Aeglea
  • Investors & Media
  • Patients & Families
Select Page
  • Investors & Media
    • Company Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports and Proxy
      • SEC Filings
    • Governance
      • Governance Documents
      • Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Investors & Media
    • Company Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports and Proxy
      • SEC Filings
    • Governance
      • Governance Documents
      • Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts

Governance Documents

  • Investors & Media
    • Company Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports and Proxy
      • SEC Filings
    • Governance
      • Governance Documents
      • Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts

Committee Charters

Download item year list
Download Description
Audit Committee (opens in new window)
445 KB
Compensation Committee (opens in new window)
196 KB
Nominating and Corporate Governance Committee (opens in new window)
439 KB

Governance Documents

Download item year list
Download Description
Code of Conduct and Ethics (opens in new window)
240 KB
Corporate Governance Guidelines (opens in new window)
124 KB
Whistleblower and Complaint Policy (opens in new window)
94 KB

Investor Contact

investors@aeglea.com
(512) 942-2935

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Aeglea BioTherapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Aeglea BioTherapeutics Inc. to send you the requested Investor Email Alert updates.

* Required

*
*





Unsubscribe

Email Alert Sign Up Confirmation

Company

  • About
  • Leadership
  • Partnering
  • Contact

Focus

  • Enzyme Therapeutics
  • Rare Metabolic Disease
  • Publications

Programs

  • Pipeline
  • Pegzilarginase
  • AGLE-177
  • Research Programs
  • Clinical Trials

Careers

  • Job
    Openings
  • Life at Aeglea

Investors & Media

  • Company Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
  • Financials & Filings
  • Corporate Governance
  • Resources
Aeglea logo
© 2021 Aeglea BioTherapeutics. Privacy Policy Terms of Use Purchase Terms COVID-19 Statement
Powered By Q4 Inc. 5.91.0.8 (opens in new window)